NGM Biopharmaceuticals, Inc.

333 Oyster Point Boulevard
South San Francisco
California
94080
United States

Tel: 650-243-5555

About NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc. is a private biotech company dedicated to discovering and developing the next generation of medicines for the treatment of serious diseases. Our experienced scientific team has joined forces with an impressive group of industry professionals, Nobel Laureates and other distinguished researchers to form a company where innovation and cutting-edge science has provided the foundation for a robust drug discovery engine. To date, NGM Bio has generated a pipeline of six drug candidates in various stages of development, including NGM282 that recently demonstrated proof-of-concept in a Phase 2 study in non-alcoholic steatohepatitis (NASH). We have many more in preclinical development. In 2015, we entered into a broad, strategic collaboration with Merck that will provide us with the resources and flexibility to pursue our ambitious R&D goals and further extend our pipeline of novel drug candidates.

22 articles with NGM Biopharmaceuticals, Inc.

NGM Bio Announces Publication In The Lancet Of Phase 2 Study Of NGM282 In NASH Patients And Upcoming Presentations Of NGM282 NASH Histology Data And NGM282 PSC Data At The International Liver Congress 2018

3/12/2018

Statistically significant and clinically meaningful improvements observed in MRI measures of liver fat and serum biomarkers of liver function, lipid metabolism and fibrosis
Ablexis Announces Licensing of the AlivaMab Mouse to NGM Biopharmaceuticals

1/5/2018

The non-exclusive license grants NGM rights to use the AlivaMab Mouse for antibody drug discovery and development.
NGM Bio Provides Update on NGM282 in NASH

10/19/2017

NGM Bio today provided an update on the development of NGM282, a compound in Phase 2 clinical testing for the treatment of NASH.
NGM Release: Study Published In Nature Reveals Molecular Pathway Of Weight-Controlling Hormone, Enabling The Discovery Of Multiple Drug Candidates For Obesity And Cachexia

10/3/2017
NGM Announces NGM282 Dramatically Reduced Liver Fat And Other Biomarkers Associated With Nonalcoholic Steatohepatitis (NASH) In Phase II Trial

4/24/2017
NGM Initiates Phase 1 Clinical Trial Of NGM313, A Proprietary Antibody With The Potential To Treat Type 2 Diabetes, Obesity And NASH

6/8/2016
Nine Bay Area Biotechs Vie to be the “Next Genentech”

5/26/2016
Booming Bay Area Biotech NGM Plans Move to Vacant Site Once Meant for Amgen

5/5/2016
NGM To Present New Data On NGM282 At The European Association For The Study Of The Liver International Liver Congress 2015

4/20/2015
NGM Announces Positive Phase II Clinical Data In Primary Biliary Cirrhosis Patients For NGM282, A First-In-Class Investigational Medicine

3/24/2015
Backed By a Genentech Alum, NGM Looks Like it Could be the Next Biotech IPO

3/5/2015
NGM Announces Expansion Of Management Team

3/2/2015
How Merck & Co.'s R&D Chief Saved NGM Deal With a Juicy Pitch

2/27/2015
Merck & Co. Bets $450 Million on Bay Area's NGM

2/24/2015
NGM Biopharmaceuticals, Inc. Locks Down $50 Million Series C

7/18/2013
AstraZeneca PLC and NGM Biopharmaceuticals, Inc. Form Diabetes/Obesity Partnership

6/17/2013
NGM Biopharmaceuticals, Inc., Led by Genentech Vets Levinson and Goeddel, Raises $13.5 Million

5/6/2013
NGM Biopharmaceuticals, Inc., Janssen Pharmaceutical K.K. Form Alliance for Undisclosed Amount

1/3/2013
NGM Biopharmaceuticals, Inc. and Daiichi Sankyo, Inc. Collaborate to Discover and Develop Innovative Therapeutics for Diabetes

3/29/2012
NGM Biopharmaceuticals, Inc. Names William J. Rieflin Chief Executive Officer and Director

10/5/2010